Lexicon Pharmaceuticals (LXRX) Price & Analysis

Compare

1,687 Followers

LXRX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.28 - $2.18

Previous CloseN/A

Volume2.02M

Average Volume (3M)2.12M

Market Cap

$407.01M

Enterprise Value$266.27M

Total Cash (Recent Filing)$139.01M

Total Debt (Recent Filing)$61.45M

Price to Earnings (P/E)―

Beta2.50

Next Earnings

Oct 30, 2025

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.01

Shares Outstanding363,398,860

10 Day Avg. Volume1,786,731

30 Day Avg. Volume2,118,526

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.65

Enterprise Value/Revenue4.56

Enterprise Value/Gross Profit4.61

Enterprise Value/Ebitda-2.42

Forecast

1Y Price Target

$2.75

Price Target Upside150.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Financial AgreementsThe exclusive licensing agreement with Novo Nordisk significantly strengthens Lexicon's financial position, providing a cushion that should allow Lexicon to focus resources on pilavapadin's Ph.3 program in DPNP and the Ph.3 SONATA trial for sotagliflozin in Hypertrophic Cardiomyopathy (HCM).

Regulatory DevelopmentsA Type D meeting with the FDA is anticipated, which may support regulatory alignment for a path forward for ZYNQUISTA.

Therapeutic InnovationsPilavapadin is validated as a non-opioid therapeutic candidate for diverse chronic neuropathic pain conditions.

Bears Say

Clinical Trial EfficacyThe Ph.2b PROGRESS study data for pilavapadin in Diabetic Peripheral Neuropathic Pain (DPNP) shows modest efficacy versus placebo.

Operational ChallengesLexicon has notably lowered its FY2025 operating expense guidance, primarily driven by a revised R&D expense projection, largely due to the transfer of costs to Novo Nordisk under the licensing agreement.

Lexicon Pharmaceuticals News

Lexicon announces presents data from Phase 2 PROGRESS study for pilavapadin

Lexicon (LXRX) Pharmaceuticals announced the presentation of clinical data from the company’s Phase 2b PROGRESS study for its...

16h ago

LXRX

Lexicon submits additional data to FDA for benefit-risk profile of Zynquista

Lexicon (LXRX) Pharmaceuticals announced that the Company has submitted additional clinical data to the U.S. Food and Drug...

10d ago

LXRX

Lexicon announces post-hoc analysis of clinical data presented at ESC

Lexicon (LXRX) Pharmaceuticals announced that a post-hoc analysis of clinical data was presented Sunday, August 31, during an...

16d ago

LXRX

Lexicon Pharmaceuticals: Promising Phase 2b Results for Pilavapadin Support Buy Rating

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals, retaining the price target of...

11h ago

LXRX

Promising Preclinical Data and FDA Alignment Support Buy Rating for Lexicon Pharmaceuticals’ Pilavapadin

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals, with...

7d ago

LXRX

Lexicon Pharmaceuticals: Promising Drug Developments and Positive Regulatory Path Boost Buy Rating

Lexicon Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from...

10d ago

LXRX

Lexicon Pharmaceuticals’ Sotagliflozin Shows Promising Cardiovascular Benefits, Earning Buy Rating

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals, retaining the price target of...

15d ago

LXRX

Lexicon Pharmaceuticals Advances Study on Sotagliflozin for Hypertrophic Cardiomyopathy

Lexicon Pharmaceuticals (($LXRX)) announced an update on their ongoing clinical study. Study Overview: Lexicon Pharmaceuticals is conducting a...

1M ago

LXRX

Balanced Outlook for Lexicon Pharmaceuticals Amid Strategic Gains and Revenue Challenges

Analyst Roanna Ruiz of Leerink Partners maintained a Hold rating on Lexicon Pharmaceuticals, retaining the price target of...

1M ago

LXRX

Citi ups Lexicon target, opens ‘upside catalyst watch’

Citi raised the firm’s price target on Lexicon (LXRX) to $1.90 from $1.20 and keeps a Buy rating...

1M ago

LXRX

Lexicon Pharmaceuticals Reports Strong Q2 2025 Results

Lexicon Pharmaceuticals ( ($LXRX) ) has released its Q2 earnings. Here is a breakdown of the information Lexicon...

1M ago

LXRX

Lexicon Pharmaceuticals Reports Strong Q2 2025 Earnings

Lexicon Pharmaceuticals (($LXRX)) has held its Q2 earnings call. Read on for the main highlights of the call....

1M ago

LXRX

Lexicon Pharmaceuticals: Strategic R&D Advancements and Strong Financial Performance Justify Buy Rating

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals, retaining the price target of...

1M ago

LXRX

Lexicon reports Q2 EPS 1c, consensus (8c)

Reports Q2 revenue $28.866M vs $1.647M last year. “We continue to make great strides against the strategy we...

1M ago

LXRX

LXRX FAQ

What was Lexicon Pharmaceuticals’s price range in the past 12 months?

Lexicon Pharmaceuticals lowest stock price was $0.28 and its highest was $2.17 in the past 12 months.

What is Lexicon Pharmaceuticals’s market cap?

Lexicon Pharmaceuticals’s market cap is $407.01M.

When is Lexicon Pharmaceuticals’s upcoming earnings report date?

Lexicon Pharmaceuticals’s upcoming earnings report date is Oct 30, 2025 which is in 42 days.

How were Lexicon Pharmaceuticals’s earnings last quarter?

Lexicon Pharmaceuticals released its earnings results on Aug 06, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.075 by $0.085.

Is Lexicon Pharmaceuticals overvalued?

According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Lexicon Pharmaceuticals pay dividends?

Lexicon Pharmaceuticals does not currently pay dividends.

What is Lexicon Pharmaceuticals’s EPS estimate?

Lexicon Pharmaceuticals’s EPS estimate is -0.07.

How many shares outstanding does Lexicon Pharmaceuticals have?

Lexicon Pharmaceuticals has 363,398,860 shares outstanding.

What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?

Lexicon Pharmaceuticals reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.075. Following the earnings report the stock price went up 9.524%.

Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?

Currently, no hedge funds are holding shares in LXRX

Lexicon Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-65.30%

Trailing 12-Months

Asset Growth

-39.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Lexicon Pharmaceuticals

Lexicon Pharmaceuticals (LXRX) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for the treatment of human disease. The company primarily operates in the pharmaceutical sector, specializing in drug development for conditions such as metabolic and neurodegenerative diseases. Lexicon's core products include LX9211, a treatment for diabetic neuropathic pain, and LX2761, aimed at addressing type 1 diabetes, among others.

Lexicon Pharmaceuticals (LXRX) Earnings & Revenues

Historic Earnings Reports

LXRX Company Deck

LXRX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call for Lexicon Pharmaceuticals was largely positive, marked by significant revenue growth, successful strategic repositioning to an R&D-focused company, and promising advancements in the drug pipeline. However, challenges remain in terms of reduced cash reserves and the dependence on partnerships for future progress.View all LXRX earnings summaries

LXRX Stock 12 Month Forecast

Average Price Target

$2.75

▲(150.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","3":"$3","5":"$5","7":"$7","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.85</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.12,1.4953846153846155,1.870769230769231,2.246153846153846,2.621538461538462,2.996923076923077,3.3723076923076922,3.747692307692308,4.123076923076923,4.498461538461538,4.873846153846154,5.24923076923077,5.624615384615384,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.12,1.2453846153846155,1.370769230769231,1.4961538461538462,1.6215384615384616,1.746923076923077,1.8723076923076922,1.9976923076923077,2.123076923076923,2.2484615384615383,2.373846153846154,2.499230769230769,2.6246153846153844,{"y":2.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.12,1.0992307692307692,1.0784615384615386,1.0576923076923077,1.036923076923077,1.0161538461538462,0.9953846153846154,0.9746153846153847,0.9538461538461539,0.9330769230769231,0.9123076923076923,0.8915384615384615,0.8707692307692307,{"y":0.85,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.73,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.46,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >